Structural insight into selectivity of amylin and calcitonin receptor agonists.

[1]  P. Sexton,et al.  A structural basis for amylin receptor phenotype , 2022, Science.

[2]  H. Xu,et al.  Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors , 2022, Nature Communications.

[3]  H. Grill,et al.  Hypophagia induced by salmon calcitonin, but not by amylin, is partially driven by malaise and is mediated by CGRP neurons , 2022, Molecular metabolism.

[4]  S. Fulle,et al.  Development of Cagrilintide, a Long-Acting Amylin Analogue. , 2021, Journal of medicinal chemistry.

[5]  K. Raun,et al.  A selective role for receptor activity‐modifying proteins in subchronic action of the amylin selective receptor agonist NN1213 compared with salmon calcitonin on body weight and food intake in male mice , 2021, The European journal of neuroscience.

[6]  T. Kruse,et al.  Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity , 2021, Journal of the Endocrine Society.

[7]  P. Sexton,et al.  AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists , 2021, The Journal of Pharmacology and Experimental Therapeutics.

[8]  David J. Fleet,et al.  3D Variability Analysis: Resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM. , 2021, Journal of structural biology.

[9]  C. Langmead,et al.  Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. , 2020, Molecular cell.

[10]  E. Tajkhorshid,et al.  Membrane Interactions of Cy3 and Cy5 Fluorophores and Their Effects on Membrane-Protein Dynamics. , 2020, Biophysical journal.

[11]  T. Lutz,et al.  Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases. , 2020, Basic & clinical pharmacology & toxicology.

[12]  M. Karsdal,et al.  The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy , 2020, The Journal of Pharmacology and Experimental Therapeutics.

[13]  P. Sexton,et al.  Structure and Dynamics of Adrenomedullin Receptors AM1 and AM2 Reveal Key Mechanisms in the Control of Receptor Phenotype by Receptor Activity-Modifying Proteins. , 2020, ACS pharmacology & translational science.

[14]  M. Brimble,et al.  Distinct Patterns of Internalization of Different Calcitonin Gene-Related Peptide Receptors. , 2020, ACS pharmacology & translational science.

[15]  L. B. Knudsen,et al.  The Discovery and Development of Liraglutide and Semaglutide , 2019, Front. Endocrinol..

[16]  W. Baumeister,et al.  Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor , 2018, Nature.

[17]  Arthur Christopoulos,et al.  Dominant Negative G Proteins Enhance Formation and Purification of Agonist-GPCR-G Protein Complexes for Structure Determination. , 2018, ACS pharmacology & translational science.

[18]  D. Hay,et al.  Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25 , 2018, British journal of pharmacology.

[19]  M. Karsdal,et al.  Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog. , 2017, American journal of physiology. Endocrinology and metabolism.

[20]  Arthur Christopoulos,et al.  Phase-plate cryo-EM structure of a class B GPCR-G protein complex , 2017, Nature.

[21]  D. Agard,et al.  MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy , 2017, Nature Methods.

[22]  David J. Fleet,et al.  cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.

[23]  Rebekah L. Bower,et al.  Amylin structure–function relationships and receptor pharmacology: implications for amylin mimetic drug development , 2016, British journal of pharmacology.

[24]  S. Brunell,et al.  Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials , 2016, Advances in Therapy.

[25]  N. Grigorieff,et al.  CTFFIND4: Fast and accurate defocus estimation from electron micrographs , 2015, bioRxiv.

[26]  D. Hay,et al.  Amylin: Pharmacology, Physiology, and Clinical Potential , 2015, Pharmacological Reviews.

[27]  Arthur Christopoulos,et al.  Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations , 2013, Proceedings of the National Academy of Sciences.

[28]  Klaus Schulten,et al.  Cryo-electron microscopy modeling by the molecular dynamics flexible fitting method. , 2012, Biopolymers.

[29]  N. Binkley,et al.  A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The oral calcitonin in postmenopausal osteoporosis (ORACAL) trial , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  T. Lutz.  Control of energy homeostasis by amylin , 2012, Cellular and Molecular Life Sciences.

[31]  Roman A. Laskowski,et al.  LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..

[32]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[33]  S. Davis,et al.  Pramlintide and the treatment of diabetes: a review of the data since its introduction , 2011, Expert opinion on pharmacotherapy.

[34]  D. Singh-Franco,et al.  The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta‐analysis , 2011, Diabetes, obesity & metabolism.

[35]  B. Roland,et al.  Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight , 2010, International Journal of Obesity.

[36]  P. Sexton,et al.  Identification of N-Terminal Receptor Activity-Modifying Protein Residues Important for Calcitonin Gene-Related Peptide, Adrenomedullin, and Amylin Receptor Function , 2008, Molecular Pharmacology.

[37]  P. Sexton,et al.  Distinct Receptor Activity-Modifying Protein Domains Differentially Modulate Interaction with Calcitonin Receptors , 2006, Molecular Pharmacology.

[38]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[39]  M Morfis,et al.  Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. , 1999, Molecular pharmacology.

[40]  Christopher J. Williams,et al.  MolProbity: More and better reference data for improved all‐atom structure validation , 2018, Protein science : a publication of the Protein Society.